146 related articles for article (PubMed ID: 25628223)
1. Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers.
Khanna A; Pimanda JE
Int J Cancer; 2016 Feb; 138(3):525-32. PubMed ID: 25628223
[TBL] [Abstract][Full Text] [Related]
2. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
3. The role of CIP2A in cancer: A review and update.
Soofiyani SR; Hejazi MS; Baradaran B
Biomed Pharmacother; 2017 Dec; 96():626-633. PubMed ID: 29035828
[TBL] [Abstract][Full Text] [Related]
4. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A; Böckelman C; Hemmes A; Junttila MR; Wiksten JP; Lundin M; Junnila S; Murphy DJ; Evan GI; Haglund C; Westermarck J; Ristimäki A
J Natl Cancer Inst; 2009 Jun; 101(11):793-805. PubMed ID: 19470954
[TBL] [Abstract][Full Text] [Related]
5. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
6. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
7. CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis.
He H; Wu G; Li W; Cao Y; Liu Y
Diagn Mol Pathol; 2012 Sep; 21(3):143-9. PubMed ID: 22847158
[TBL] [Abstract][Full Text] [Related]
8. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
De P; Carlson J; Leyland-Jones B; Dey N
Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
[TBL] [Abstract][Full Text] [Related]
10. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein.
Liu J; Wang X; Zhou G; Wang H; Xiang L; Cheng Y; Liu W; Wang Y; Jia J; Zhao W
Gynecol Oncol; 2011 Aug; 122(2):430-6. PubMed ID: 21575984
[TBL] [Abstract][Full Text] [Related]
11. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Lucas CM; Harris RJ; Giannoudis A; Copland M; Slupsky JR; Clark RE
Blood; 2011 Jun; 117(24):6660-8. PubMed ID: 21490338
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma.
Yang X; Qu K; Tao J; Yin G; Han S; Liu Q; Sun H
Biochem Biophys Res Commun; 2018 Jan; 495(2):1807-1814. PubMed ID: 29175329
[TBL] [Abstract][Full Text] [Related]
13. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Birkman EM; Elzagheid A; Jokilehto T; Avoranta T; Korkeila E; Kulmala J; Syrjänen K; Westermarck J; Sundström J
Cancer Med; 2018 Mar; 7(3):698-706. PubMed ID: 29441695
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CIP2A expression in solid tumors: A meta-analysis.
Tang M; Shen JF; Li P; Zhou LN; Zeng P; Cui XX; Chen MB; Tian Y
PLoS One; 2018; 13(7):e0199675. PubMed ID: 30044786
[TBL] [Abstract][Full Text] [Related]
16. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
17. CIP2A overexpression is associated with c-Myc expression in colorectal cancer.
Böckelman C; Koskensalo S; Hagström J; Lundin M; Ristimäki A; Haglund C
Cancer Biol Ther; 2012 Mar; 13(5):289-95. PubMed ID: 22310977
[TBL] [Abstract][Full Text] [Related]
18. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1.
Kim JS; Kim EJ; Oh JS; Park IC; Hwang SG
Cancer Res; 2013 Nov; 73(22):6667-78. PubMed ID: 23983103
[TBL] [Abstract][Full Text] [Related]
19. [Expression of cancerous inhibitor of protein phosphatase 2A in tissue microarray of colorectal cancer and its clinical significance].
Peng XY; Chen W; Zhou K; Fu JP; Fu P; Zeng QL
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1102-6. PubMed ID: 24277410
[TBL] [Abstract][Full Text] [Related]
20. The association and prognostic relevance of cancerous inhibitor of protein phosphatase 2A and inflammation in tongue squamous cell carcinoma.
Seppälä M; Tervo S; Pohjola K; Laranne J; Huhtala H; Toppila-Salmi S; Paavonen T
APMIS; 2015 Dec; 123(12):1007-15. PubMed ID: 26522733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]